Robert Celt
New Member
Leamington's medical cannabis producer Aphria is expanding.
The expansion will see the facility double its size and include an oil extraction room, chemistry laboratory and microbiology lab, according to the company's chief financial officer Carl Merton. Currently, Aphria only sells medical marijuana, but the increased space will allow further research towards the development of oil extraction sales, Merton said.
Health Canada awarded Aphria its licence to produce cannabis oil in August 2015, nine months after receiving its licence to grow marijuana.
"It's been hard to convince Mrs. Smith, who is 70-80 years old and going through cancer treatment to smoke marijuana in a joint," he said. "It would be easier for her to use the oil, which she can put on her tongue or take in a capsule and get the same relief."
Merton said Aphria now supplies close to 3,800 patients.
In anticipation of the expansion, the company hired six new employees and plans to hire four more people. The company estimates the combined facility could generate up to $30 million in sales annually.
"Aphria continues to deliver on its long-term strategic plan," chief executive officer Vic Neufeld said in a press release. "The additional growing space allows us to meet increased demands for medical marijuana from our rapidly growing client base."
Medical cannabis has been prescribed to help manage chronic pain arising from such conditions as arthritis, cancer, fibromyalgia, multiple sclerosis and spinal cord injury.
News Moderator: Robert Celt 420 MAGAZINE ®
Full Article: Medical Cannabis Company To Double Its Leamington Facilites
Author: Kelly Steele
Contact: Windsor Star
Photo Credit: Dan Janisse
Website: Windsor Star
The expansion will see the facility double its size and include an oil extraction room, chemistry laboratory and microbiology lab, according to the company's chief financial officer Carl Merton. Currently, Aphria only sells medical marijuana, but the increased space will allow further research towards the development of oil extraction sales, Merton said.
Health Canada awarded Aphria its licence to produce cannabis oil in August 2015, nine months after receiving its licence to grow marijuana.
"It's been hard to convince Mrs. Smith, who is 70-80 years old and going through cancer treatment to smoke marijuana in a joint," he said. "It would be easier for her to use the oil, which she can put on her tongue or take in a capsule and get the same relief."
Merton said Aphria now supplies close to 3,800 patients.
In anticipation of the expansion, the company hired six new employees and plans to hire four more people. The company estimates the combined facility could generate up to $30 million in sales annually.
"Aphria continues to deliver on its long-term strategic plan," chief executive officer Vic Neufeld said in a press release. "The additional growing space allows us to meet increased demands for medical marijuana from our rapidly growing client base."
Medical cannabis has been prescribed to help manage chronic pain arising from such conditions as arthritis, cancer, fibromyalgia, multiple sclerosis and spinal cord injury.
News Moderator: Robert Celt 420 MAGAZINE ®
Full Article: Medical Cannabis Company To Double Its Leamington Facilites
Author: Kelly Steele
Contact: Windsor Star
Photo Credit: Dan Janisse
Website: Windsor Star
